Table 1.
General characteristics of the cohort.
| Parameters | Total (n = 337) | Females (n = 281) | Males (n = 56) |
|---|---|---|---|
| Age | |||
| Mean (SD) | 33.7 (10.2) | 32.4 (9.2) | 38.2 (11.9) |
| Median (IQR) | 31 (25.9–40) | 30.3 (25.5–37.1) | 38.2(29.7–45.4) |
| HPV+ | |||
| Genital | 73.6% (248/337) | 73.7% (207/281) | 73.2 (41/56) |
| Oral | 10.1% (34/337) | 7.1% (20/281) | 25% (14/56) |
| HrHPV (including lrHPV/hrHPV infections) | |||
| Genital | 86.7% (215/248) | 87% (180/207) | 82.9% (34/41) |
| Oral | 70.6% (24/34) | 65% (13/20) | 78.6% (11/14) |
| Single infections | |||
| Genital | 62.1% (154/248) | 67.1% (139/207) | 36.6% (15/41) |
| Oral | 91.2% (31/34) | 95% (19/20) | 85.7% (12/14) |
| Multiple infections | |||
| Genital | 37.9% (94/248) | 32.9% (68/207) | 63.4% (26/41) |
| Oral | 8.8% (3/34) | 5% (1/20) | 14.3% (2/14) |
| Concurrence | 12.5% (31/248) | 9.2% (19/207) | 29.3% (12/41) |
| hr-concordance | 61.3% (19/31) | 57.9% (11/19) | 66.7% (8/12) |
| lr-concordance | 12.9% (4/31) | 15.8% (3/19) | 8.3% (1/12) |
| Type-concordance | 25.8% (10/31) | 31.6% (6/19) | 33.3% (4/12) |
| Genotype included in the quadrivalent vaccine | |||
| Genital | 35.1% (87/248) | 31.9% (66/207) | 51.2% (21/41) |
| Oral | 35.3% (12/34) | 30% (6/20) | 42.9% (6/14) |
| Genotype included in the nonavalent vaccine | |||
| Genital | 61.7% (153/248) | 59.4% (123/207) | 73.2% (30/41) |
| Oral | 44.1% (15/34) | 40% (8/20) | 50% (7/14) |
lr = low risk; hr = high risk.